@claudeai Can you guys please fix chat. I used to work for 3+ hours on Opus before hitting cap, now it’s literally 1 ask, 10 minutes and tokens done for 5 hours. Even with Sonnet!!?!?!
This study identifies the wide range of interventions required to realise patient access in a non-profit R&D model and the critical role and enabling attributes of an ‘orchestrator’ to steer a complex set of actors towards the shared goal of reach.
Link: https://t.co/WtB0hhjRwH
@bryan_johnson@PaulAustin3w Would be interesting to know how low you can go to experience the benefits. Is a hero dose 25mg needed or is a hallucinogenic 10mg sufficient. Would impact scalability.
Violence against women is one of the oldest and most persistent health problems, yet least acted upon.
An estimated 840 million women globally – 1 in 3 women – have faced violence at least once in their lifetime including 263 million who have suffered sexual violence. Behind every statistic is a woman or girl whose life has been forever altered.
We urge governments, law makers, policy makers, families, communities, and health systems to work together to make sure women and girls are empowered and safe everywhere. This is prerequisite for peace, development and health.
https://t.co/w2sKNtEz9G
Media Release: SAHPRA Registers Lenacapavir
SAHPRA has officially registered Lenacapavir, a groundbreaking antiviral injection developed by Gilead for HIV-1 prevention. Recommended alongside safer sex practices, Lenacapavir provides six-monthly protection for HIV-negative adults and adolescents weighing at least 35 kg. This approval, supported by the EU-M4all procedure and the European Medicines Agency, marks a significant step in accelerating access to essential medicines and strengthening regulatory collaboration.
Find out more: https://t.co/MI384714Lc
@bryan_johnson If you had to pick a list of biomarkers that can be done anywhere in the world (im not in the US) as a starting point, most bang for buck for modifiable risks or early management - what would that include?
Voters create GNU 🗳️
👇
GNU launches reforms for growth 🤝
👇
Confidence in SA increases 📈
👇
Rand strengthens 💵
👇
Fuel and other prices decrease ⛽️
👇
Inflation declines 📉
👇
Interest rates cut ✂️
👇
Economy primed for more jobs and more money in your pocket! 💰
Pushed on whether parties should abide by an ICJ ruling on Israel, StateSpox Patel gets called out by Matt Lee:
“you’ve called for the Chinese to respect those decisions, are you saying now that you’re withholding judgment on whether countries should obey a verdict of the ICJ?”
Bedaquiline saves lives, every day it is not used is a day hundreds, perhaps thousands of lives are lost. Affordable access now, globally, is imperative.
It is false to suggest—as some recently have—that our patents are being used to prevent access to SIRTURO® (bedaquiline), our medicine for MDR-TB.
In fact, we have already entered into a collaboration with the Stop TB Partnership’s Global Drug Facility (“GDF”)—the largest procurer of TB medicines—which enables them to invite potential generic suppliers and purchase generic versions of SIRTURO® 100mg. On April 5, during a World Health Organization meeting, the GDF shared its intent to launch a tender for generic versions of SIRTURO® 100mg in the third quarter of 2023: https://t.co/6m49h5g7tn
In addition, we have shipped more than 660,000 courses of SIRTURO® to 159 countries since launch. Our patents made this possible, enabling us to assist countries to scale-up their use of our medicine responsibly and sustainably and invest in multiple, critical, anti-TB efforts. For instance, in the face of rising drug resistance, we support stewardship efforts that ensure MDR-TB patients can benefit from our medicine today and in the future.
Unfortunately, the most significant barrier to treatment access for patients today is the fact that millions of patients with TB go undiagnosed every year. This is a challenge that we have invested significant resources to overcome and must all get behind if we are to achieve the global goal of ending TB.
Early bactericidal activity studies for TB have been conducted for decades. Our collaboration with the incredible team at Uppsala has resulted in a review and standardization of the methods, which supports our exploration of novel designs in EBA https://t.co/HmJb3QEAXn